Alcohol Use Disorder

  1. Overview and DSM-5 Classification
  2. Pathophysiology: Acute Effects
  3. Neuroadaptation and Tolerance
  4. Alcohol Withdrawal Syndrome
  5. Medical Complications
  6. Diagnosis and Screening
  7. Medical Detoxification
  8. Pharmacotherapy
  9. Behavioral Treatments
  10. Key Research Papers
  11. Featured Videos

Overview and DSM-5 Classification

Alcohol Use Disorder (AUD) is a chronic, relapsing brain disorder characterized by compulsive alcohol use, loss of control over drinking, and a negative emotional state when not drinking. The DSM-5 unified the former categories of alcohol abuse and alcohol dependence into a single dimensional diagnosis, graded as mild (2–3 criteria), moderate (4–5 criteria), or severe (6 or more of 11 criteria) based on symptom count over the preceding 12 months.

AUD is one of the most prevalent psychiatric conditions in the United States. Approximately 14.4 million adults (5.8% of those aged 18 and older) meet diagnostic criteria, along with an estimated 401,000 adolescents aged 12–17. Alcohol contributes to roughly 88,000 deaths per year in the US, making it the third leading preventable cause of death, behind tobacco and poor diet or physical inactivity.

The disorder sits at the intersection of psychiatry, internal medicine, and public health. Despite effective treatments existing — both pharmacological and psychosocial — fewer than 10% of people with AUD receive any treatment in a given year, reflecting the substantial treatment gap driven by stigma, cost, and limited access.

Back to Table of Contents

Pathophysiology: Acute Effects

Ethanol is a small, lipophilic molecule that crosses the blood-brain barrier rapidly and exerts its intoxicating effects primarily through two receptor systems:

Additionally, ethanol increases dopamine release in the mesolimbic reward pathway (ventral tegmental area to nucleus accumbens), reinforcing repeated use. It also interacts with opioid receptors — endogenous opioid release triggered by alcohol contributes to the pleasurable, euphoric component of drinking, a mechanism directly targeted by naltrexone.

At high blood alcohol concentrations (>0.25 g/dL), brainstem depression can produce respiratory suppression, aspiration risk, and death — the mechanism of acute alcohol poisoning.

Back to Table of Contents

Neuroadaptation and Tolerance

With chronic heavy alcohol exposure, the brain compensates for persistent GABA-A potentiation and NMDA inhibition through homeostatic neuroadaptation:

Neuroimaging and post-mortem studies also document reduced gray matter volume in the prefrontal cortex (PFC), impairing executive function, impulse control, and decision-making — the very faculties needed to regulate drinking. These PFC changes correlate with relapse risk and improve partially (but not completely) with sustained abstinence. The dopamine reward system is also dysregulated: baseline dopamine tone falls, making ordinary pleasures less rewarding ("anhedonia") and making alcohol the primary reliable pleasure trigger — a hallmark of addiction.

Neuroadaptation explains why stopping suddenly is dangerous, why cravings persist long into sobriety (opponent-process model), and why early relapse rates are high even among genuinely motivated individuals.

Back to Table of Contents

Alcohol Withdrawal Syndrome

When a neuroadapted brain is abruptly deprived of alcohol, the compensatory upregulation of excitatory (NMDA) systems and downregulation of inhibitory (GABA-A) systems creates CNS hyperexcitability — the physiological basis of the alcohol withdrawal syndrome (AWS). AWS is not simply uncomfortable; it can be life-threatening.

Timeline of withdrawal symptoms:

The CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised) is the validated 10-item scale used to quantify withdrawal severity and guide symptom-triggered benzodiazepine dosing. Scores ≥10 warrant pharmacological treatment; scores ≥15–20 indicate severe withdrawal requiring close monitoring.

Back to Table of Contents

Medical Complications

Chronic heavy alcohol use injures virtually every organ system. The most clinically significant complications include:

Liver: The liver metabolizes ~90% of ingested ethanol. The progression of alcoholic liver disease follows a well-defined spectrum:

Brain — Wernicke-Korsakoff Syndrome: Thiamine (vitamin B1) deficiency — almost universal in severe AUD due to poor diet, impaired gut absorption, and reduced hepatic storage — precipitates:

Peripheral neuropathy: Length-dependent axonal neuropathy (distal stocking-glove sensory loss, burning pain, weakness) affects ~25–50% of patients with AUD and is caused by both direct ethanol toxicity and B-vitamin deficiencies.

Cardiovascular: Alcoholic cardiomyopathy (dilated cardiomyopathy from direct myocardial toxicity), atrial fibrillation ("holiday heart"), and hypertension are all common. Light-to-moderate drinking may have modest cardioprotective effects in some populations, but heavy drinking is clearly cardiotoxic and the J-curve relationship is contested in recent Mendelian randomization studies.

Pancreatitis: Both acute and chronic pancreatitis are strongly associated with heavy drinking; alcohol accounts for 30–35% of acute pancreatitis cases and up to 70–80% of chronic pancreatitis.

Cancer: The IARC classifies ethanol as a Group 1 carcinogen. Alcohol causally increases risk for at least seven cancers: oral cavity, pharynx, larynx, esophagus, liver, colorectum, and female breast. There is no established safe threshold.

Fetal Alcohol Spectrum Disorder (FASD): Prenatal alcohol exposure is the leading preventable cause of intellectual disability and congenital birth defects. Fetal alcohol syndrome (FAS) — the full syndrome — includes growth restriction, characteristic facial features, and CNS abnormalities. FASD represents the full spectrum of less severe but still significant neurodevelopmental effects.

Back to Table of Contents

Diagnosis and Screening

AUD is a clinical diagnosis based on DSM-5 criteria. The patient must meet at least 2 of the following 11 criteria in a 12-month period:

  1. Drinking more or longer than intended.
  2. Repeated unsuccessful attempts to cut down or stop.
  3. Spending a great deal of time obtaining, using, or recovering from alcohol.
  4. Strong craving or urge to drink.
  5. Failure to fulfill major role obligations at work, school, or home.
  6. Continued use despite persistent social or interpersonal problems caused by alcohol.
  7. Giving up important activities because of alcohol.
  8. Repeated use in physically hazardous situations.
  9. Continued use despite knowing a physical or psychological problem is caused or worsened by alcohol.
  10. Tolerance (needing more for the same effect).
  11. Withdrawal symptoms when stopping or cutting down.

Validated screening tools:

Laboratory biomarkers:

Back to Table of Contents

Medical Detoxification

Medical detoxification manages the acute withdrawal syndrome safely; it is not itself a treatment for AUD but a necessary first step enabling subsequent treatment. Setting (inpatient vs. outpatient) is determined by withdrawal severity, history of seizures or DTs, comorbid medical conditions, and social supports.

Benzodiazepines are first-line for AWS, acting as GABA-A positive allosteric modulators — they "replace" ethanol's inhibitory effect while allowing gradual dose taper:

Phenobarbital serves as an adjunct or alternative for benzodiazepine-refractory withdrawal, acting on both GABA-A and NMDA systems. Evidence for phenobarbital-alone protocols in the ED is growing.

IV thiamine (100–500 mg) MUST be given before any glucose-containing fluids in all patients with suspected AUD to prevent precipitation or worsening of Wernicke encephalopathy. Thiamine stores may be depleted to days in severely malnourished patients; IV route ensures absorption regardless of gut dysfunction.

Magnesium supplementation addresses frequent deficiency and may reduce seizure threshold. Multivitamin supplementation addresses broad B-vitamin deficiency.

Back to Table of Contents

Pharmacotherapy for Alcohol Use Disorder

Three FDA-approved medications reduce drinking or support abstinence. All are under-prescribed — fewer than 5% of patients with AUD receive pharmacotherapy.

Naltrexone is a competitive μ-opioid receptor antagonist. By blocking opioid receptors, it prevents the endorphin-mediated pleasurable reward of drinking, reducing the urge to continue once started ("cue-induced craving blunting"). Available as:

Acamprosate (calcium acetylhomotaurinate) modulates NMDA and GABA receptor systems, reducing the glutamate-driven hyperexcitability and anxiety that characterize protracted abstinence. Evidence is strongest for supporting abstinence in already-detoxified patients.

Disulfiram (Antabuse) inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion. The resulting flushing, nausea, vomiting, tachycardia, and hypotension (disulfiram-ethanol reaction) deter drinking through aversive conditioning.

Gabapentin (off-label): Increasingly used for both alcohol withdrawal and relapse prevention. A 2014 JAMA Internal Medicine RCT showed gabapentin 1800 mg/day significantly reduced heavy drinking and improved sleep and mood vs. placebo. Its GABA-mimetic and anti-craving properties, combined with safety in liver disease and favorable side-effect profile, make it an attractive option.

Topiramate (off-label): GABA facilitation and glutamate antagonism; multiple RCTs show reduction in heavy drinking days and drinks per day. Cognitive side effects (word-finding difficulty) and metabolic acidosis limit tolerability.

Back to Table of Contents

Behavioral Treatments

Pharmacotherapy alone is insufficient; behavioral and psychosocial treatments address the cognitive, emotional, and social dimensions of AUD. These are most effective when combined with medication.

Residential treatment, partial hospitalization, and intensive outpatient programs (IOP) provide structured environments for severe AUD or those without a stable, sober home environment. The American Society of Addiction Medicine (ASAM) criteria guide level-of-care placement decisions.

Back to Table of Contents

Key Research Papers

Back to Table of Contents

Connections